TPG Biotech is the life sciences venture capital platform of TPG, a leading global alternative asset manager. Established in 2002, TPG Biotech focuses on investing in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, and industrial applications of biotechnology. The firm leverages TPG's extensive resources and expertise to support companies developing disruptive science, technologies, and business models aimed at improving patient outcomes in areas with significant unmet medical needs.

TPG Biotech's investment strategy is thematic, concentrating on sectors such as oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, as well as commercial-stage medical devices and tech-enabled services. The team brings deep scientific, clinical, and operational expertise to its investments, partnering with companies from early-stage development through clinical trials to commercialization. This approach is built upon TPG's market-leading healthcare franchise, which has invested over $30 billion across the global healthcare ecosystem since 2003.